PATENT CLAIM ANALYSIS

Application Number: 15986536
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "322000"]

Abstract:
The present invention provides methods of administering a PARP inhibitor to a cancer patient.

Claim (Index 119):
A method of treating a patient having a recurrent cancer selected from ovarian cancer, fallopian tube cancer, or peritoneal cancer comprising administering niraparib to the patient according to a regimen determined to achieve i) prolonged progression free survival as compared to control, ii) a reduced hazard ratio for disease progression or death as compared to control, iii) prolonged overall survival as compared to control, or iv) an overall response rate of at least 30%.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 93.0
- Lexical Diversity: 1.07143
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15852551', '15337274', '15433249', '14772549', '14717069']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7276140724668658
- 35 USC 102 Novelty (BERT): 0.533990923590892
- Combined Prediction Score: 0.7082517575792685
- Mean Citation Score: 324.554998
- Max Citation Score: 359.90317000000016
- Similarity Product: 237.14619189350552

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test